176 related articles for article (PubMed ID: 35778228)
21. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study.
Nery F; Chevret S; Condat B; de Raucourt E; Boudaoud L; Rautou PE; Plessier A; Roulot D; Chaffaut C; Bourcier V; Trinchet JC; Valla DC;
Hepatology; 2015 Feb; 61(2):660-7. PubMed ID: 25284616
[TBL] [Abstract][Full Text] [Related]
22. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study.
Qi X; He C; Guo W; Yin Z; Wang J; Wang Z; Niu J; Bai M; Yang Z; Fan D; Han G
Liver Int; 2016 May; 36(5):667-76. PubMed ID: 26235541
[TBL] [Abstract][Full Text] [Related]
23. Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome.
Fujiyama S; Saitoh S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
BMC Gastroenterol; 2017 Oct; 17(1):112. PubMed ID: 29070023
[TBL] [Abstract][Full Text] [Related]
24. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis.
Amitrano L; Guardascione MA; Brancaccio V; Margaglione M; Manguso F; Iannaccone L; Grandone E; Balzano A
J Hepatol; 2004 May; 40(5):736-41. PubMed ID: 15094219
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Coagulation, Fibrinolysis and Endothelial Biomarkers in Cirrhotic Patients With or Without Portal Venous Thrombosis.
Ren W; Zhang J; Chen Y; Wen M; Su Y; Zhao Y; Lu S; Wu J
Clin Appl Thromb Hemost; 2020; 26():1076029620982666. PubMed ID: 33356499
[TBL] [Abstract][Full Text] [Related]
26. Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate.
Faccia M; Ainora ME; Ponziani FR; Riccardi L; Garcovich M; Gasbarrini A; Pompili M; Zocco MA
World J Gastroenterol; 2019 Aug; 25(31):4437-4451. PubMed ID: 31496623
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis.
Noronha Ferreira C; Reis D; Cortez-Pinto H; Tato Marinho R; Gonçalves A; Palma S; Leite I; Rodrigues T; Pedro AJ; Alexandrino P; Serejo F; Sobral Dias M; Ferreira P; Vasconcelos M; Damião F; Xavier Brito L; Baldaia C; Fatela N; Ramalho F; Velosa J
Dig Dis Sci; 2019 Sep; 64(9):2671-2683. PubMed ID: 30852769
[TBL] [Abstract][Full Text] [Related]
28. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis.
Luca A; Miraglia R; Caruso S; Milazzo M; Sapere C; Maruzzelli L; Vizzini G; Tuzzolino F; Gridelli B; Bosch J
Gut; 2011 Jun; 60(6):846-52. PubMed ID: 21357252
[TBL] [Abstract][Full Text] [Related]
29. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development.
Zocco MA; Di Stasio E; De Cristofaro R; Novi M; Ainora ME; Ponziani F; Riccardi L; Lancellotti S; Santoliquido A; Flore R; Pompili M; Rapaccini GL; Tondi P; Gasbarrini GB; Landolfi R; Gasbarrini A
J Hepatol; 2009 Oct; 51(4):682-9. PubMed ID: 19464747
[TBL] [Abstract][Full Text] [Related]
30. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
Mandorfer M; Schwabl P; Paternostro R; Pomej K; Bauer D; Thaler J; Ay C; Quehenberger P; Fritzer-Szekeres M; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferlitsch A;
Aliment Pharmacol Ther; 2018 Apr; 47(7):980-988. PubMed ID: 29377193
[TBL] [Abstract][Full Text] [Related]
31. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
32. Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big picture.
Gîrleanu I; Trifan A; Stanciu C; Sfarti C
World J Gastroenterol; 2018 Oct; 24(39):4419-4427. PubMed ID: 30356984
[TBL] [Abstract][Full Text] [Related]
33. Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
Amjad W; Jiang Z; Lai M
J Gastroenterol Hepatol; 2024 May; 39(5):955-963. PubMed ID: 38273643
[TBL] [Abstract][Full Text] [Related]
34. A single hospital study on portal vein thrombosis in cirrhotic patients - clinical characteristics & risk factors.
Chen H; Trilok G; Wang F; Qi X; Xiao J; Yang C
Indian J Med Res; 2014 Feb; 139(2):260-6. PubMed ID: 24718401
[TBL] [Abstract][Full Text] [Related]
35. Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort.
Cool J; Rosenblatt R; Kumar S; Lucero C; Fortune B; Crawford C; Jesudian A
J Gastroenterol Hepatol; 2019 Jun; 34(6):1088-1092. PubMed ID: 30307066
[TBL] [Abstract][Full Text] [Related]
36. Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response.
Mandorfer M; Turon F; Lens S; Baiges A; García-Criado Á; Darnell A; Belmonte E; Ferrusquía-Acosta J; Magaz M; Perez-Campuzano V; Olivas P; Bauer D; Casanovas G; Torres F; Mariño Z; Forns X; Hernández-Gea V; García-Pagán JC
Liver Int; 2021 Dec; 41(12):2954-2964. PubMed ID: 34242479
[TBL] [Abstract][Full Text] [Related]
37. Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features.
Jha RC; Khera SS; Kalaria AD
AJR Am J Roentgenol; 2018 Jul; 211(1):14-24. PubMed ID: 29792748
[TBL] [Abstract][Full Text] [Related]
38. The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients.
Zampino R; Lebano R; Coppola N; Macera M; Grandone A; Rinaldi L; De Sio I; Tufano A; Stornaiuolo G; Adinolfi LE; Durante-Mangoni E; Battista GG; Niglio A
Saudi J Gastroenterol; 2018; 24(1):25-29. PubMed ID: 29451181
[TBL] [Abstract][Full Text] [Related]
39. Portal vein thrombosis and liver cirrhosis: Long-term anticoagulation is effective and safe.
Bergère M; Erard-Poinsot D; Boillot O; Valette PJ; Guillaud O; Chambon-Augoyard C; Dumortier J
Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):395-402. PubMed ID: 30578107
[TBL] [Abstract][Full Text] [Related]
40. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.
Langholm LL; Manon-Jensen T; Karsdal MA; Bendtsen F; Leeming DJ; Møller S
Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1040-1048. PubMed ID: 30768435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
